

# John Soucie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3144092/publications.pdf>

Version: 2024-02-01

67  
papers

5,367  
citations

117453

34  
h-index

102304

66  
g-index

68  
all docs

68  
docs citations

68  
times ranked

2987  
citing authors

#	ARTICLE	IF	CITATIONS
1	Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States. <i>Haemophilia</i> , 2022, 28, .	1.0	3
2	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. <i>Haemophilia</i> , 2021, 27, 445-453.	1.0	13
3	Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. <i>Blood Advances</i> , 2021, 5, 2079-2086.	2.5	4
4	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1035-1045.	1.0	3
5	Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. <i>Haemophilia</i> , 2020, 26, 487-493.	1.0	41
6	Evaluation of CDC's Hemophilia Surveillance Program's Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States. <i>MMWR Surveillance Summaries</i> , 2020, 69, 1-18.	18.6	26
7	Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. <i>Haemophilia</i> , 2019, 25, 575-580.	1.0	6
8	Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources. <i>Haemophilia</i> , 2019, 25, 456-462.	1.0	15
9	Global Hemophilia Care: Data for Action. <i>Annals of Internal Medicine</i> , 2019, 171, 585.	2.0	5
10	Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. <i>Pediatrics</i> , 2018, 141, e20173485.	1.0	15
11	The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. <i>Blood Advances</i> , 2018, 2, 2136-2144.	2.5	69
12	Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010. <i>Haemophilia</i> , 2018, 24, 964-970.	1.0	5
13	Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. <i>Blood</i> , 2017, 129, 2368-2374.	0.6	121
14	The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States. <i>Haemophilia</i> , 2017, 23, e287-e293.	1.0	28
15	Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. <i>Haemophilia</i> , 2017, 23, e1-e7.	1.0	10
16	Prophylaxis use among males with haemophilia B in the United States. <i>Haemophilia</i> , 2017, 23, 910-917.	1.0	8
17	Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. <i>Haemophilia</i> , 2017, 23, 207-214.	1.0	56
18	Men with severe hemophilia in the United States: birth cohort analysis of a large national database. <i>Blood</i> , 2016, 127, 3073-3081.	0.6	93

#	ARTICLE	IF	CITATIONS
19	NHFâ€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 6-16.	1.0	50
20	Care models in the management of haemophilia: a systematic review. Haemophilia, 2016, 22, 31-40.	1.0	20
21	Characteristics of hemophilia patients with factor <scp>VIII</scp> inhibitors detected by prospective screening. American Journal of Hematology, 2015, 90, 871-876.	2.0	11
22	Cluster of inhibitors among adult inpatients with haemophilia in a single institution. Haemophilia, 2015, 21, e325-e328.	1.0	0
23	Impact of inhibitors on hemophilia a mortality in the <scp>U</scp>nited <scp>S</scp>tates. American Journal of Hematology, 2015, 90, 400-405.	2.0	127
24	Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia, 2015, 21, e39-43.	1.0	15
25	A Public Health Approach to the Prevention of Inhibitors in Hemophilia. American Journal of Preventive Medicine, 2014, 47, 669-673.	1.6	10
26	Prevalent inhibitors in haemophilia <scp>B</scp> subjects enrolled in the <scp>U</scp>niversal <scp>D</scp>ata <scp>C</scp>ollection database. Haemophilia, 2014, 20, 25-31.	1.0	56
27	Association of overweight and obesity with the use of self and homeâ€based infusion therapy among haemophilic men. Haemophilia, 2014, 20, 340-348.	1.0	12
28	A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia, 2014, 20, 230-237.	1.0	37
29	The national haemophilia program standards, evaluation and oversight systems in the United States of America. Blood Transfusion, 2014, 12 Suppl 3, e542-8.	0.3	3
30	Evidence for the continued transmission of parvovirus <scp>B</scp>19 in patients with bleeding disorders treated with plasmaâ€derived factor concentrates. Transfusion, 2013, 53, 1143-1144.	0.8	8
31	Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasmaâ€derived factor concentrates in the era of nucleic acid test screening. Transfusion, 2013, 53, 1217-1225.	0.8	40
32	The effect of secondary prophylaxis <i>versus</i> episodic treatment on the range of motion of target joints in patients with haemophilia. British Journal of Haematology, 2013, 161, 424-433.	1.2	21
33	Comparison of clotâ€based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. Journal of Thrombosis and Haemostasis, 2013, 11, 1300-1309.	1.9	56
34	Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the <scp>UDC</scp> database. Haemophilia, 2013, 19, 426-431.	1.0	14
35	Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia, 2013, 19, 595-601.	1.0	12
36	Public health surveillance and data collection: general principles and impact on hemophilia care. Hematology, 2012, 17, s144-s146.	0.7	28

#	ARTICLE	IF	CITATIONS
37	Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. <i>Haemophilia</i> , 2012, 18, 268-275.	1.0	69
38	<i>F8</i> and <i>F9</i> mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. <i>Haemophilia</i> , 2012, 18, 375-382.	1.0	109
39	Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. <i>Haemophilia</i> , 2012, 18, 276-283.	1.0	63
40	Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System. <i>Haemophilia</i> , 2012, 18, 532-539.	1.0	20
41	Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. <i>Haemophilia</i> , 2012, 18, e260-5.	1.0	45
42	Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1055-1061.	1.9	92
43	Physical Functioning in Boys with Hemophilia in the U.S.. <i>American Journal of Preventive Medicine</i> , 2011, 41, S360-S368.	1.6	35
44	Knowledge and Therapeutic Gaps. <i>American Journal of Preventive Medicine</i> , 2011, 41, S324-S331.	1.6	13
45	Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. <i>British Journal of Haematology</i> , 2011, 152, 211-216.	1.2	98
46	Range of motion measurements: reference values and a database for comparison studies. <i>Haemophilia</i> , 2011, 17, 500-507.	1.0	293
47	The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. <i>Haemophilia</i> , 2011, 17, 196-203.	1.0	47
48	Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). <i>Haemophilia</i> , 2011, 17, 597-604.	1.0	63
49	Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. <i>Haemophilia</i> , 2011, 17, 6-13.	1.0	71
50	Pediatric Hemophilia: A Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 737-744.	1.5	56
51	In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2224-2231.	1.9	60
52	Burden of Disease Resulting from Hemophilia in the U.S.. <i>American Journal of Preventive Medicine</i> , 2010, 38, S482-S488.	1.6	25
53	The Universal Data Collection Surveillance System for Rare Bleeding Disorders. <i>American Journal of Preventive Medicine</i> , 2010, 38, S475-S481.	1.6	54
54	Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. <i>Haemophilia</i> , 2009, 15, 918-925.	1.0	30

#	ARTICLE	IF	CITATIONS
55	Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. <i>Haemophilia</i> , 2009, 15, 1281-1290.	1.0	127
56	Septic arthritis in males with haemophilia. <i>Haemophilia</i> , 2008, 14, 494-503.	1.0	24
57	Linking the world with training and research for improving haemophilia care. <i>Haemophilia</i> , 2008, 14, 43-48.	1.0	4
58	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. <i>New England Journal of Medicine</i> , 2007, 357, 535-544.	13.9	1,681
59	Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2576-2581.	1.9	56
60	Prevalence and risk factors for heart disease among males with hemophilia. <i>American Journal of Hematology</i> , 2005, 79, 36-42.	2.0	115
61	Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. <i>Blood</i> , 2004, 103, 2467-2473.	0.6	225
62	Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. <i>Transfusion</i> , 2004, 44, 1179-1185.	0.8	24
63	Renal disease among males with haemophilia. <i>Haemophilia</i> , 2003, 9, 703-710.	1.0	84
64	Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. <i>Haemophilia</i> , 2001, 7, 198-206.	1.0	96
65	Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. <i>American Journal of Hematology</i> , 2001, 68, 37-42.	2.0	89
66	Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. <i>Blood</i> , 2000, 96, 437-42.	0.6	266
67	Occurrence of hemophilia in the United States. , 1998, 59, 288-294.		288